What MCTs are and how they differ from regular fats
Triglycerides are the storage form of dietary fat — three fatty acid chains attached to a glycerol backbone. The fatty acids are classified by chain length: short-chain (2-5 carbons), medium-chain (6-12 carbons), and long-chain (14-22 carbons). Per Bach 1982 (American Journal of Clinical Nutrition) and the foundational Babayan 1987 (Lipids) review, MCTs are absorbed differently than long-chain fats. Long-chain triglycerides require pancreatic lipase, bile salts, and chylomicron formation; they enter the lymphatic system before reaching the liver. Medium-chain fats bypass that pathway: they cross the intestinal mucosa as free fatty acids, enter the portal vein directly, and reach the liver intact.
In the liver, MCTs are rapidly oxidized to acetyl-CoA, which can either enter the citric acid cycle for energy or be converted to ketone bodies (β-hydroxybutyrate, acetoacetate, acetone). The ketones leave the liver, circulate in the bloodstream, and serve as an alternative fuel for tissues including the brain. The brain’s ability to use ketones is the entire mechanistic basis for MCT supplementation in cognitive aging contexts.
The Pan 2010 senior cognition study — the canonical canine evidence
The most-cited canine MCT study is Pan 2010 (British Journal of Nutrition). The trial randomized 24 senior beagles (>7 years) to either a control diet or a diet enriched with 5.5% medium-chain triglycerides for 8 months. The dogs were then tested across a battery of cognitive tasks (landmark discrimination, oddity discrimination, reversal learning, egocentric vs allocentric spatial navigation). Per the published results, MCT-supplemented dogs significantly outperformed controls on multiple tasks — the magnitude of effect was comparable to that seen in published Alzheimer’s human MCT trials.
The mechanism Pan 2010 proposed is brain glucose hypometabolism. Per multiple aging neuroimaging studies, the senior brain progressively loses the ability to efficiently extract and metabolize glucose; MCT-derived ketones provide an alternative fuel that bypasses the failing glucose pathway. This is the same mechanism cited in human MCT trials for Alzheimer’s and mild cognitive impairment per Henderson 2009 (Nutrition & Metabolism).
Sources of MCT in pet food — coconut oil vs concentrated MCT
The MCT oil sold as a stand-alone supplement is typically a concentrated fraction of caprylic acid (C8:0) and capric acid (C10:0), separated from coconut or palm kernel oil through fractionation. The concentrated form is roughly 95-99% C8:0 + C10:0 by composition.
Coconut oil, often listed on dog food labels as “coconut oil” or “dried coconut,” is approximately 60-65% medium-chain fatty acids by weight, but the dominant fatty acid in coconut oil is lauric acid (C12:0), which sits at the boundary between medium-chain and long-chain classification. Per the McCarty 2015 (Open Heart) review and the Roberts 2017 (Veterinary Sciences) canine review, lauric acid is metabolized more like a long-chain fat than a true MCT — it does not produce ketones as efficiently as C8:0 or C10:0. Coconut oil at typical pet food inclusion levels delivers some MCT benefit, but at lower potency than the Pan 2010 trial inclusion of 5.5% concentrated MCT.
Purina Pro Plan Bright Mind 7+ is the most prominent commercial dog food formulated with the Pan 2010 inclusion level. The formulation was developed in partnership with Purina’s veterinary nutrition team based directly on the original research. See our Purina Pro Plan Bright Mind review for KibbleIQ’s analysis.
MCT in epilepsy management — the seizure-control angle
Per Law 2015 (BMC Veterinary Research) and the follow-up Berk 2018 (Epilepsia) double-blind randomized trial, dogs with idiopathic epilepsy supplemented with MCT-enriched diet showed reduced seizure frequency compared to placebo control. The mechanism is shared with the ketogenic diet’s seizure-control effect in human epilepsy: ketones produce a tonic anticonvulsant effect via GABAergic and glutamate signaling modulation. The AAHA 2018 Senior Care Guidelines and the ACVIM 2015 Consensus Statement on Idiopathic Epilepsy both note MCT as an adjunct to standard antiepileptic drug therapy — not a replacement, but a supplemental tool that can reduce drug dose in some cases.
Practical considerations — dose, palatability, GI tolerance
The Pan 2010 trial used MCT at 5.5% of dry matter, equivalent to roughly 6-8 g/day for a typical 10 kg dog. Pet owners supplementing on top of a regular diet typically start at 0.25-0.5 mL per 4.5 kg body weight and titrate upward over 7-14 days. The most common side effect is GI upset — soft stool or transient diarrhea — which usually resolves with slower titration. Per Berk 2018, palatability is excellent in dogs; refusal is rare. Per AAFCO Official Publication 2024, MCT and coconut oil are both approved as fat sources in pet food formulations.
How KibbleIQ scores MCT oil and coconut oil
The KibbleIQ Dry Kibble Rubric v15 awards a small positive credit for MCT-enriched senior or cognitive-support formulations when the inclusion level approaches the Pan 2010 trial dose (≥4-5% on a dry-matter basis). Coconut oil at lower inclusion levels (1-3%) earns a smaller positive credit reflecting the diminished MCT functional content. The rubric does not penalize formulations that omit MCT — the evidence base is supportive but not strong enough to make MCT an expected ingredient in any non-CDS adult formula. See our cognitive decline guide and turmeric explainer for adjacent senior-support context. To check your bag, paste the ingredient list into the KibbleIQ analyzer.